24 HR dapagliflozin 10 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Xigduo]

What the CMS Formulary Data Shows for 24 HR dapagliflozin 10 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Xigduo]

Under the CMS Quarterly Prescription Drug Plan Formulary, Pharmacy Network, and Pricing public-use file for the 2026 contract year, 24 HR dapagliflozin 10 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Xigduo] (RxNorm concept RXCUI 1593775, generic name 24) appears on 310 distinct formulary files spanning 4,710 Medicare Part D plan offerings. That equates to a national coverage rate of 93% of enrollable Part D products — a near-universal placement that most beneficiaries will find on whichever PDP or MA-PD contract they enroll in. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 2.7; lower tiers correspond to lower beneficiary copays or coinsurance under the plan's standard benefit design.

Utilization-management restrictions materially change how easily a beneficiary can actually fill 24 HR dapagliflozin 10 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Xigduo] after enrollment. 0% of covering formularies require prior authorization — meaning the prescribing clinician must submit clinical justification to the plan before the pharmacy can dispense. 0.3% require step therapy, forcing trial of a lower-cost alternative first. 91.9% apply quantity limits on a per-fill or per-month basis. These three levers — PA, step therapy, and QL — are the standard Part D cost-containment tools and are recorded plan-by-plan in the CMS formulary file, so two plans listing the same tier can still differ sharply on actual dispensability.

Medicare Part D spending dashboard figures are not published for this drug. The table below shows every PDP and MA-PD currently listing 24 HR dapagliflozin 10 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Xigduo]. Before enrolling, confirm the exact tier, prior-authorization status, and pharmacy-network pricing for your ZIP code using Medicare Plan Finder — the beneficiary-facing true-out-of-pocket amount depends on your stage within the Part D benefit (deductible, initial coverage, and the 2026 catastrophic cap at $2,000 annual OOP). This page is informational only; drug therapy decisions should be made with a licensed clinician and pharmacist.